Fusen Pharmaceutical Co (HKSE:01652) 5-Year EBITDA Growth Rate : -38.30% (As of Jun. 2024)

View and export this data going back to 2018. Start your Free Trial

What is Fusen Pharmaceutical Co 5-Year EBITDA Growth Rate?

Fusen Pharmaceutical Co's EBITDA per Share for the six months ended in Jun. 2024 was HK$-0.05.

During the past 12 months, Fusen Pharmaceutical Co's average EBITDA Per Share Growth Rate was -893.30% per year. During the past 3 years, the average EBITDA Per Share Growth Rate was -44.60% per year. During the past 5 years, the average EBITDA Per Share Growth Rate was -38.30% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average EBITDA per share growth rate.

During the past 9 years, the highest 3-Year average EBITDA Per Share Growth Rate of Fusen Pharmaceutical Co was 14.00% per year. The lowest was -44.60% per year. And the median was -23.80% per year.

Competitive Comparison of Fusen Pharmaceutical Co's 5-Year EBITDA Growth Rate

For the Drug Manufacturers - Specialty & Generic subindustry, Fusen Pharmaceutical Co's 5-Year EBITDA Growth Rate, along with its competitors' market caps and 5-Year EBITDA Growth Rate data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Fusen Pharmaceutical Co's 5-Year EBITDA Growth Rate Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Fusen Pharmaceutical Co's 5-Year EBITDA Growth Rate distribution charts can be found below:

* The bar in red indicates where Fusen Pharmaceutical Co's 5-Year EBITDA Growth Rate falls into.

Fusen Pharmaceutical Co 5-Year EBITDA Growth Rate Calculation

This is the 5-year average growth rate of EBITDA per Share. The growth rate is calculated with least square regression.

Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average EBITDA per share growth rate.

Fusen Pharmaceutical Co (HKSE:01652) 5-Year EBITDA Growth Rate Explanation

EBITDA per Share is the amount of Earnings Before Interest, Taxes, Depreciation, and Amortization (EBITDA) per outstanding share of the company's stock.

Earnings Before Interest, Taxes, Depreciation, and Amortization (EBITDA) is what the company earns before it expenses interest, taxes, depreciation and amortization.

5-Year EBITDA Growth Rate gives an overview of the company's growth in operating profitability and is an important factor used in calculating Peter Lynch Fair Value.

Fusen Pharmaceutical Co 5-Year EBITDA Growth Rate Related Terms

Thank you for viewing the detailed overview of Fusen Pharmaceutical Co's 5-Year EBITDA Growth Rate provided by GuruFocus.com. Please click on the following links to see related term pages.

Fusen Pharmaceutical Co Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Fusen Pharmaceutical Co Ltd (HKSE:01652) » Definitions » 5-Year EBITDA Growth Rate

Traded in Other Exchanges

N/A

Address

Urban Industrial Zone, Henan Province, Xichuan County, Zhengzhou, CHN

Website

http://www.fusenyy.com

Fusen Pharmaceutical Co Ltd is engaged in manufacturing shuanghuanglian based cold medicine. The product portfolio company includes shuanghuanglian based cold medicines which include oral solutions and shuanghuanglian injections, other PCM and western medicine products which include compound ferrous sulphate granules and flunarizine hydrochloride capsules.

Executives

Cao Changcheng	2201 Interest of corporation controlled by you
Quan Xiufeng	2202 Interest of your spouse
Full Bliss Holdings Limited	2101 Beneficial owner
One Victory Investments Limited	2101 Beneficial owner
Cao Zhiming	2201 Interest of corporation controlled by you
Zhou Peilin	2202 Interest of your spouse
Rayford Global Limited	2306 Nominee for another person
Tct (bvi) Limited	2501 Other
The Core Trust Company Limited	2301 Trustee
First Joint Elegant Limited	2101 Beneficial owner
Fung Wai Sze	2202 Interest of your spouse
Lam Yiu Por	2201 Interest of corporation controlled by you

Fusen Pharmaceutical Co Headlines

No Headlines